Overview

AMG 827 in Rheumatoid Arthritis Subjects With Inadequate Response to Methotrexate

Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
Randomized, double-blind, placebo-controlled study in subjects with RA who have an inadequate response to methotrexate.
Phase:
Phase 2
Details
Lead Sponsor:
Amgen
Treatments:
Antibodies, Monoclonal
Brodalumab
Methotrexate